reports
MediWound Ltd: 1 director
A director at MediWound Ltd bought 18,462 shares at 17.130USD and the significance rating of the trade was 79/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx...
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. The event will focus on EscharEx®, an innovative biologic drug in late-stage clinical development for chronic wound debridement, including the upcoming Phas...
MediWound Reports Third Quarter 2024 Financial Results and Provides Co...
MediWound Reports Third Quarter 2024 Financial Results and Provides Company Update EscharEx IND Submission by Year-End; Phase 3 Study to Begin Shortly Thereafter; KOL Event Set for January 8, 2025 FDA Approves NexoBrid for Pediatric Use $25 Million Financing and €16.25 Million EIC Funding Strengthen Cash Runway to Profitability NexoBrid Product Revenue Meets Expectations; Demand Exceeds Capacity as New Manufacturing Facility Commissioning Underway Conference Call Today, November 26 at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 26, 2024 (GLOBE NEWSWIRE) -- MediWoun...
MediWound to Report Third Quarter 2024 Financial Results
MediWound to Report Third Quarter 2024 Financial Results Conference Call and Webcast Scheduled for Tuesday, November 26, 2024, at 8:30 a.m. Eastern Time YAVNE, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will release its financial results for the third quarter ended September 30, 2024, on Tuesday, November 26, 2024. Following the release, MediWound’s management will host a conference call and live webcast at 8:30 a.m. Eastern Time to discuss these financia...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® v...
MediWound Announces Phase II Head-to-Head Study Evaluating EscharEx® vs. Collagenase in Patients with Venous Leg Ulcers Secured additional R&D collaborations with Solventum and Mölnlycke for optimal trial consistency and patient outcomes Study to support EscharEx® BLA submission and strengthen commercialization strategy YAVNE, Israel, Oct. 10, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it will be initiating a controlled, multicenter Phase II clinical study evaluating EscharEx...
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit
MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET. To attend the virtual fireside chat, please register . In addition, the Medi...
MediWound to Present at the H.C. Wainwright 26th Annual Global Investm...
MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference YAVNE, Israel, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Ofer Gonen, Chief Executive Officer, will participate in a fireside chat, hosted by Swayampakula Ramakanth, Managing Director, Senior Equity Research, on Tuesday, September 10, 2024 at 3:30 p.m. ET at the H.C. Wainwright 26th Annual Global Investment Conference. A live webcast of the event will be accessible both and on M...
MediWound Announces U.S. Food and Drug Administration Approval of Nexo...
MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages YAVNE, Israel, Aug. 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for NexoBrid® (anacaulase-bcdb) allowing for eschar removal in pediatr...
MediWound Reports Second Quarter 2024 Financial Results and Provides C...
MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update Completed Construction of New NexoBrid® Manufacturing Facility €16.25 Million EIC Funding Expedites EscharEx® Development for Diabetic Foot Ulcers, Significantly Expanding the Addressable Market; Phase III Study for Venous Leg Ulcers to Begin in H2 2024 $25 Million Strategic Investment Led by Mölnlycke Health Care Conference Call Today, August 14 at 8:30am Eastern Time YAVNE, Israel, Aug. 14, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-gener...
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded ...
MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT) NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients YAVNE, Israel, Aug. 05, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced the positive results of the NEXT—an Expanded Access Protocol. NEXT, initiated in 2019, aimed to ensure the continuous availability of NexoBrid® in burn centers until its commercialization. This...
MediWound to Report Second Quarter 2024 Financial Results
MediWound to Report Second Quarter 2024 Financial Results Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time YAVNE, Israel, Aug. 02, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the second quarter ended June 30, 2024 on Wednesday, August 14, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Stud...
MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers Research Published in THE LANCET's eClinicalMedicineEscharEx® Outperforms Non-Surgical Standard of Care in Debridement and Promotion of Healthy Granulation Tissue YAVNE, Israel, July 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announces the peer-reviewed publication on the Phase II ChronEx study assessing the safety and efficacy of EscharEx for the treatment of Venous Leg Ulcers (VLU) i...
MediWound Announces €16.25 Million Funding from the European Innovatio...
MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program Funds to be used for clinical development of EscharEx® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today it has been selected to receive €16.25 million in blended funding from the through its accelerator program. The funding...
MediWound Announces $25 Million Strategic Private Placement Financing
MediWound Announces $25 Million Strategic Private Placement Financing Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke Health Care ("Mölnlycke"), a world-leading MedTech company specializing in solutions for wound care and surgic...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
EBS EMERGENT BIOSOLUTIONS INC.
CDNA CAREDX INC
THS TREEHOUSE FOODS INC.
FONR FONAR CORP.
KIDS ORTHOPEDIATRICS CORP
AMD ADVANCED MICRO DEVICES INC.
KRYS KRYSTAL BIOTECH INC
MMMB MAMAMANCINI'S HOLDINGS INC
SITM SITIME
RNA AVIDITY BIOSCIENCES
PWP PERELLA WEINBERG PARTNERS
ASTS AST SPACEMOBILE INC
BRBR BELLRING BRANDS INC
INTR INTER & CO INC
EWTX EDGEWISE THERAPEUTICS INC
ACRV ACRIVON THERAPEUTICS INC
WGS GENEDX HOLDINGS CORP.
XPOF XPONENTIAL FITNESS INC
SOWG SOW GOOD INC
MediWound Reports First Quarter 2024 Financial Results and Provides Co...
MediWound Reports First Quarter 2024 Financial Results and Provides Company Update NexoBrid® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time YAVNE, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the first quarte...
MediWound to Report First Quarter 2024 Financial Results
MediWound to Report First Quarter 2024 Financial Results Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its financial results for the first quarter ended March 31, 2024 on Wednesday, May 29, 2024. Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide corpora...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PEP PEPSICO INC.
TXN TEXAS INSTRUMENTS INCORPORATED
TRMK TRUSTMARK CORPORATION
SWN SOUTHWESTERN ENERGY COMPANY
SMTC SEMTECH CORPORATION
SATS ECHOSTAR CORPORATION CLASS A
RRC RANGE RESOURCES CORPORATION
NFG NATIONAL FUEL GAS COMPANY
MDWD MEDIWOUND
LWAY LIFEWAY FOODS INC.
HAS HASBRO INC.
FBP FIRST BANCORP
EQT EQT CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRK COMSTOCK RESOURCES INC.
VIRT VIRTU FINANCIAL INC. CLASS A
SYF SYNCHRONY FINANCIAL
HRTG HERITAGE INSURANCE HOLDINGS INC.
BSX. BELO SUN MINING CORP.
ORN ORION GROUP HOLDINGS
ITGR INTEGER HOLDINGS CORPORATION
PE. PURE ENERGY MINERALS LTD
DESP DESPEGAR.COM CORP.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
NTB BANK OF N.T. BUTTERFIELD & SON
COOP MR. COOPER GROUP INC.
KTB KONTOOR BRANDS
ALXO ALX ONCOLOGY HOLDINGS
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
PRG PROG HOLDINGS INC
VRT VERTIV HOLDINGS CO (A)
AMAL AMALGAMATED FINANCIAL CORP
CGEM CULLINAN ONCOLOGY INC
RANI RANI THERAPEUTICS HLDGS INC
CR CRANE CO NEW
BGC BGC GROUP INC
SOWG SOW GOOD INC COM
MediWound to Present New Data from EscharEx® Phase II Studies at Three...
MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
VIRC VIRCO MANUFACTURING CORP.
MDWD MEDIWOUND
NEM NEMETSCHEK SE
ARO ARCANDOR AG
CSTE CAESARSTONE LTD.
AGX ARGAN INC.
AMRK AMARK PRECIOUS METALS
EVER EVERQUOTE
RPAY REPAY HOLDINGS (A)
IGMS IGM BIOSCIENCES
PRLD PRELUDE THERAPEUTICS
DFH DREAM FINDERS HOMES
GATO GATOS SILVER
CPNG COUPANG
TPL TEXAS PACIFIC LAND CORPORATION
RANI RANI THERAPEUTICS HLDGS INC
JANX JANUX THERAPEUTICS INC
ALVO OAKTREE ACQUISITION CORP II
IE IVANHOE ELECTRIC INC
ACRV ACRIVON THERAPEUTICS INC
IZM ICZOOM GROUP INC
CRBP CORBUS PHARMACEUTICALS HOLDINGS INC.
PRAX PRAXIS PRECISION MEDICINES INC
EGIO EDGIO INC.
FIP FIAT INDUSTRIAL SPA
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.